A Phase 1 Open -Label Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005% Applied Under Maximal Use Conditions in Adolescent Subjects With Plaque Psoriasis. J of Skin 2019, 3 (2), 171. https://doi.org/10.25251/skin.3.2.11.